Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Development | February 13, 2026 | February 18, 2026 |
| Larimar Therapeutics, Inc.ZFGN · Entity 5634 | Head of Research & Development | April 02, 2019 | April 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 10,560 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 10,560 · Balance 10,560 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
Larimar Therapeutics, Inc.
Report date April 02, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.89 · Expires 2029-03-03 | Direct | 375,000 |
Reported balance
After 2019-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-02 · Grant · Acquired 375,000 · Balance 375,000 F1: 25% of this option vests on March 4, 2020, and the remainder vests in equal monthly installments thereafter over 36 months. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). The option is subject to acceleration upon a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option vests on March 4, 2020, and the remainder vests in equal monthly installments thereafter over 36 months. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). The option is subject to acceleration upon a change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2024 Filed Feb 5, 2024 23:38 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 634 | $245.93 | $155,919.62 |
DisclosureSEC source: 0001127602-24-003440 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,097.0915 Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:38 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,828 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003440 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,657 Underlying: Common Stock · 1,828 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 1, 2023 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:38 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 561 | $247.83 | $139,032.63 |
DisclosureSEC source: 0001127602-24-003440 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,731.0915 Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:38 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003440 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,292.0915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:36 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantPerformance Stock Unit · Derivative | 819 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-002813 · form4.xml · derivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 819 Underlying: Common Stock · 819 shares Expires 2024-02-18 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 18, 2021. The PSUs will vest on February 18, 2024. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 110 | $248.00 | $27,280.00 |
DisclosureSEC source: 0001127602-23-029445 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,464.0915 Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 426 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-029445 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 426 Underlying: Common Stock · 426 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on December 8, 2021 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 206 | $239.29 | $49,293.74 |
DisclosureSEC source: 0001127602-23-029445 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,574.0915 Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 426 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-029445 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,780.0915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 431 | $269.43 | $116,124.33 |
DisclosureSEC source: 0001127602-23-023824 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,354.0915 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,668 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023824 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,337 Underlying: Common Stock · 1,668 shares Expires 2025-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on September 1, 2022 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 807 | $267.17 | $215,606.19 |
DisclosureSEC source: 0001127602-23-023824 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,785.0915 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-023824 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,592.0915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 21:33 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 81 | $282.87 | $22,912.47 |
DisclosureSEC source: 0001127602-23-020235 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,924.0915 Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 315 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020235 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 315 shares Expires 2023-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on July 1, 2020 and vested in three equal installments on each anniversary of the grant date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 153 | $284.85 | $43,582.05 |
DisclosureSEC source: 0001127602-23-020235 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,005.0915 Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:33 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020235 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,158.0915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 22:37 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 91 | $277.11 | $25,217.01 |
DisclosureSEC source: 0001127602-23-012691 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,843.0915 F1 · price: Includes 91.6992 shares acquired under the Biogen Inc. employee stock purchase plan. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 22:31 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 568 | $270.06 | $153,394.08 |
DisclosureSEC source: 0001127602-23-011661 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,842.3923 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:13 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 341 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-009142 · form4.xml · derivative · entry 5 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 341 shares Expires 2023-03-02 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: This award was granted to the reporting person on March 2, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 297 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-009142 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341 Underlying: Common Stock · 297 shares Expires 2023-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award was granted to the reporting person on March 2, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 144 | $268.75 | $38,700.00 |
DisclosureSEC source: 0001127602-23-009142 · form4.xml · nonDerivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,410.3923 Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 297 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-009142 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,554.3923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:13 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 543 | $268.75 | $145,931.25 |
DisclosureSEC source: 0001127602-23-009142 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,257.3923 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:07 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 408 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006527 · form4.xml · derivative · entry 4 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874 Underlying: Common Stock · 408 shares Expires 2024-02-18 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of Restricted Stock Units ("RSUs") reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 460 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006527 · form4.xml · derivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282 Underlying: Common Stock · 460 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of Restricted Stock Units ("RSUs") reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 151 | $278.38 | $42,035.38 |
DisclosureSEC source: 0001127602-23-006527 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800.3923 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 460 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006527 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,951.3923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,211 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005267 · form4.xml · derivative · entry 3 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,424 Underlying: Common Stock · 1,211 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 10, 2022 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 372 | $286.30 | $106,503.60 |
DisclosureSEC source: 0001127602-23-005267 · form4.xml · nonDerivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,491.3923 Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:21 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005267 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,863.3923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:35 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 5,485 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003460 · form4.xml · derivative · entry 2 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,485 Underlying: Common Stock · 5,485 shares Expires 2026-02-01 F1 · derivative.exercise_date: This award was granted to the reporting person on February 1, 2023 and will vest in three equal installments on each anniversary of the grant date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 23:01 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002485 · form4.xml · nonDerivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,652.3923 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on March 2, 2020. The shares will vest on March 2, 2023. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 22:37 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0000899243-19-010033 · doc4.xml · derivative · entry 1 Singhal Priya · CIK 0001769608 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2029-03-03 F1 · derivative.exercise_date: 25% of this option vests on March 4, 2020, and the remainder vests in equal monthly installments thereafter over 36 months. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). The option is subject to acceleration upon a change in control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.